Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 365

The DOI matches its Crossref record.

Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply

Ryden, L., Standl, E. · 2007 · European Heart Journal

Abstract

Thank you for forwarding the letter of the distinguished colleagues, Andre Scheen and Luc Van Gaal, and the opportunity to respond. The potential of rimonabant, the first representative of a new class of drugs, the CB1-receptor blocker, to induce weight loss and beneficial metabolic effects in support of a healthier lifestyle are undoubtedly impressive (references 3 and 4 of the letter). Guidelines, however, are to be based on available evidence in the form of published, full papers at the time they are consented. In view of this pre-condition, we regret that the rimonabant data in patients with diabetes were published after the complex work of the guideline-producing process had been terminated. Moreover, some of these data are still available in the abstract format only (reference 5 of the letter). When time comes to update the Joint ESC/EASD Guidelines on Diabetes, Prediabetes and Cardiovascular Diseases, we certainly foresee the need to consider also the state of affair in terms of rimonabant. By that time, it would be rather helpful if the weight-reducing and metabolic effects in high-risk patients with type 2 diabetes could be shown to indeed translate into a reduction of major cardiovascualar events or appropriate surrogate markers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehm124

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 365

Metadata

Authors
Ryden, L., & Standl, E.
Venue
European Heart Journal
Published
2007-06-01
Volume
28
Issue
11
Pages
1402-1402
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W4234314368
Cited by
365
References
0
FWCI
29.78
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply. https://app.cochat.ai/papers/10.1093/eurheartj/ehm124
The paper
Ryden, L., & Standl, E. (2007). Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply. European Heart Journal. https://doi.org/10.1093/eurheartj/ehm124

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.